Towards consistency in pediatric brain tumor measurements: Challenges, solutions, and the role of artificial intelligence-based segmentation.

IF 16.4 1区 医学 Q1 CLINICAL NEUROLOGY Neuro-oncology Pub Date : 2024-09-05 DOI:10.1093/neuonc/noae093
Ariana M Familiar, Anahita Fathi Kazerooni, Arastoo Vossough, Jeffrey B Ware, Sina Bagheri, Nastaran Khalili, Hannah Anderson, Debanjan Haldar, Phillip B Storm, Adam C Resnick, Benjamin H Kann, Mariam Aboian, Cassie Kline, Michael Weller, Raymond Y Huang, Susan M Chang, Jason R Fangusaro, Lindsey M Hoffman, Sabine Mueller, Michael Prados, Ali Nabavizadeh
{"title":"Towards consistency in pediatric brain tumor measurements: Challenges, solutions, and the role of artificial intelligence-based segmentation.","authors":"Ariana M Familiar, Anahita Fathi Kazerooni, Arastoo Vossough, Jeffrey B Ware, Sina Bagheri, Nastaran Khalili, Hannah Anderson, Debanjan Haldar, Phillip B Storm, Adam C Resnick, Benjamin H Kann, Mariam Aboian, Cassie Kline, Michael Weller, Raymond Y Huang, Susan M Chang, Jason R Fangusaro, Lindsey M Hoffman, Sabine Mueller, Michael Prados, Ali Nabavizadeh","doi":"10.1093/neuonc/noae093","DOIUrl":null,"url":null,"abstract":"<p><p>MR imaging is central to the assessment of tumor burden and changes over time in neuro-oncology. Several response assessment guidelines have been set forth by the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groups in different tumor histologies; however, the visual delineation of tumor components using MRIs is not always straightforward, and complexities not currently addressed by these criteria can introduce inter- and intra-observer variability in manual assessments. Differentiation of non-enhancing tumors from peritumoral edema, mild enhancement from absence of enhancement, and various cystic components can be challenging; particularly given a lack of sufficient and uniform imaging protocols in clinical practice. Automated tumor segmentation with artificial intelligence (AI) may be able to provide more objective delineations, but rely on accurate and consistent training data created manually (ground truth). Herein, this paper reviews existing challenges and potential solutions to identifying and defining subregions of pediatric brain tumors (PBTs) that are not explicitly addressed by current guidelines. The goal is to assert the importance of defining and adopting criteria for addressing these challenges, as it will be critical to achieving standardized tumor measurements and reproducible response assessment in PBTs, ultimately leading to more precise outcome metrics and accurate comparisons among clinical studies.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376457/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noae093","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

MR imaging is central to the assessment of tumor burden and changes over time in neuro-oncology. Several response assessment guidelines have been set forth by the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working groups in different tumor histologies; however, the visual delineation of tumor components using MRIs is not always straightforward, and complexities not currently addressed by these criteria can introduce inter- and intra-observer variability in manual assessments. Differentiation of non-enhancing tumors from peritumoral edema, mild enhancement from absence of enhancement, and various cystic components can be challenging; particularly given a lack of sufficient and uniform imaging protocols in clinical practice. Automated tumor segmentation with artificial intelligence (AI) may be able to provide more objective delineations, but rely on accurate and consistent training data created manually (ground truth). Herein, this paper reviews existing challenges and potential solutions to identifying and defining subregions of pediatric brain tumors (PBTs) that are not explicitly addressed by current guidelines. The goal is to assert the importance of defining and adopting criteria for addressing these challenges, as it will be critical to achieving standardized tumor measurements and reproducible response assessment in PBTs, ultimately leading to more precise outcome metrics and accurate comparisons among clinical studies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
实现小儿脑肿瘤测量的一致性:挑战、解决方案和基于人工智能的分割的作用。
磁共振成像是评估神经肿瘤学中肿瘤负荷和随时间变化的核心。儿科神经肿瘤学反应评估(RAPNO)工作组针对不同的肿瘤组织学制定了多项反应评估指南;然而,使用核磁共振成像直观地划分肿瘤成分并不总是那么简单,而且这些标准目前尚未解决的复杂性会导致人工评估中观察者之间和观察者内部的差异。区分无增强肿瘤和瘤周水肿、轻度增强和无增强以及各种囊性成分可能具有挑战性;特别是考虑到临床实践中缺乏足够和统一的成像方案。利用人工智能(AI)进行自动肿瘤分割或许能提供更客观的划分,但这依赖于人工创建的准确一致的训练数据(地面实况)。本文回顾了识别和定义小儿脑肿瘤(PBT)亚区域的现有挑战和潜在解决方案,这些挑战和解决方案在现行指南中并未明确涉及。本文旨在强调定义和采用标准以应对这些挑战的重要性,因为这对实现标准化肿瘤测量和可重复的 PBT 反应评估至关重要,最终将带来更精确的结果指标和临床研究间的准确比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neuro-oncology
Neuro-oncology 医学-临床神经学
CiteScore
27.20
自引率
6.30%
发文量
1434
审稿时长
3-8 weeks
期刊介绍: Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.
期刊最新文献
Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy. EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. EDA2R reflects the acute brain response to cranial irradiation in liquid biopsies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1